PsychedelicNewsBreaks

WednesdayJun 17, 2020 1:25 pm

PsychedelicNewsBreaks – Mind Medicine Inc. (NEO: MMED) (OTCQB: MMEDF) Announces Phase 2 Clinical Trial of LSD to Treat Cluster Headaches Begins Treating Patients

Mind Medicine (NEO: MMED) (OTCQB: MMEDF) (“MindMed”), a leading neuro-pharmaceutical company focused on psychedelic inspired medicines, recently announced that the Phase 2 clinical trial evaluating LSD for the treatment of cluster headaches at University Hospital Basel's Liechti Lab has started treating patients. MindMed previously established an ongoing R&D collaboration with the University Hospital Basel's Liechti Lab to evaluate various therapeutic uses of psychedelics and next-gen psychedelic therapies. The double-blind, randomized, placebo-controlled two-phase cross-over study is examining the effects of an oral LSD pulse regimen in 30 patients with cluster headaches. “As we continue on our mission to discover, develop and…

Continue Reading

MondayJun 15, 2020 9:41 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Provides Corporate Update

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, on Friday provided a corporate update. Since commencing trading on March 2, 2020, the Company has expanded its initiatives and rapidly executed on such initiatives to position it as a leading publicly traded psychedelic medicine company developing novel rapid onset treatments for depression, post-traumatic stress disorder (“PTSD”), and substance-use disorders (“SUD”) via the clinical delivery of ketamine and ketamine-derivatives. In the update, the Company shared its corporate advancements and achievements over the last quarter, which target key segments in…

Continue Reading

MondayJun 08, 2020 11:11 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Engages Toronto-based Dalriada to Advance NCE IP Portfolio

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, today announced its selection of Toronto-based Dalriada Drug Discovery Inc. (“Dalriada”) to advance its new chemical entity (“NCE”) IP portfolio as it pertains to ketamine and psilocybin/psilicin molecular scaffolds. According to the update, Dalriada, a leading contract research organization (“CRO”) in the drug discovery space, will lead Champignon’s new drug discovery programs in the NCE arena and further provide integrated R&D support to accelerate the Company’s existing preclinical assets and ongoing development of proprietary delivery platforms. “It is with…

Continue Reading

ThursdayJun 04, 2020 2:14 pm

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Names New CEO

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human-optimization sciences company with an emphasis on ketamine and psychedelic medicine, recently named Dr. Roger McIntyre as chief executive officer. An article discussing the company reads, “In his new role, Dr. Roger McIntyre brings impressive experience in the ketamine and psychedelic medicine space, a key focus area for Champignon. . . . ‘My overarching aim as chief executive officer is to establish Champignon as the apotheosis of integrated ketamine treatment delivery and the commercialization of our own IP psychedelic-based treatments,’ McIntyre stated in a news release. ‘The clinical infrastructure, complementary asset…

Continue Reading

FridayMay 29, 2020 10:09 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces Voluntary Share Lock-Up, Engagement of Gold Standard Media for Marketing and Consulting Services

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, today announced that certain shareholders have agreed to a voluntary resale restriction period covering 17,840,000 common shares extending the period of time before the shares become free trading to July 15, 2020. According to the update, these shares were previously only subject to a statutory hold period. In addition, Champignon Brands also announced its engagement of Gold Standard Media, LLC (“GSM”) to provide marketing and consulting services to raise public awareness of the company, with a specific emphasis on…

Continue Reading

TuesdayMay 26, 2020 9:17 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Appoints New Member to Board of Directors

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, on Monday announced the appointment of Dr. Bill Wilkerson, LL.D. (Hon), an 8-time award-winning pioneer in workplace mental health, to its board of directors. In addition, the company reported the resignation of Mr. Joe Perino from its board of directors. “We are thrilled to welcome Dr. Wilkerson to our board of directors. I look forward to working with him on a personal level as his decades of thought leadership in mental health and extensive global network will be vital…

Continue Reading

FridayNov 22, 2019 3:24 pm

PsychedelicNewsBreaks – Hemptown USA Strategically Positioned to Become Largest North American Producer of CBD

Hemptown USA, a privately owned grower of full-spectrum, feminized hemp using premium-seed genetics, operates a farm operation with more than 500 acres dedicated to the cultivation of nonpsychoactive cannabigerol (“CBG”). The company’s recent harvest positioned it to be the largest producer of CBG in North America. An article discussing the company reads, “Hemptown USA has built CBD production from broad-spectrum hemp biomass in states such as Oregon, Kentucky and California, but has worked to increase its profile as hemp-friendly laws have been enacted — particularly last year’s farm bill that legalized commercial hemp cultivation nationwide following years of prohibition. .…

Continue Reading

ThursdayOct 31, 2019 9:24 am

PsychedelicNewsBreaks – SinglePoint, Inc. (SING) Launches 1606 Original Hemp

Technology and investment company SinglePoint (OTCQB: SING) this morning announced the release of its new wholly owned brand, 1606 Original Hemp, marking the company’s entrance into the smokable hemp market. The brand will offer an array of smokable hemp products that will not stimulate psychoactive effects like those found in marijuana products, because hemp has less than 0.3% THC while marijuana contains 5%-35% THC. The company plans to expand the brand swiftly through retail, distribution, and a new ecommerce site that is currently under development. To view the full press release, visit http://cnw.fm/LKti9 About SinglePoint Inc. SinglePoint is a technology…

Continue Reading

TuesdayMay 21, 2019 2:47 pm

PsychedelicNewsBreaks – Wildflower Brands Inc.’s (CSE: SUN) (OTCQB: WLDFF) CBD Immunity Vaporizer Fights Flu Symptoms

Wildflower Brands (CSE: SUN) (OTCQB: WLDFF), is a Vancouver-based company emphasizing on wellness and health plant-based products. Michelle Lhooq, author of the article 'The Best CBD and Hemp Products for the Tasteful Non-Stoner' on the Strategist, boasts about Wildflower’s CBD Immunity Vaporizer disposable vapes. The unique mixture of CBD, cinnamon eucalyptus, and myrrh help  boost the immune system while providing a non-psychoactive effect. It is available for purchase on the company’s website for $59.99 (http://cnw.fm/7FLvs). To view the full article, visit http://cnw.fm/r1h4C About Wildflower Brands Wildflower Brands is a Vancouver-based company developing and designing brands that focus on plant-based health…

Continue Reading

MondayApr 29, 2019 2:05 pm

PsychedelicNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Innovative Technology Improves Delivery of Nicotine, Cannabinoids

Biotechnology company and drug-delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its pioneering-drug delivery platform DehydraTECH(TM), which improves the speed, taste and delivery of bioactive compounds, including nicotine and cannabinoids. A recent article discussing the company reads, “Furthermore, the DehydraTECH drug delivery platform increases bio-absorption by up to 10 times and lessens the time of onset, with effects being felt within 15 to 20 minutes, as compared to 60 to 120 minutes without the platform. In addition, the technology is patent protected for cannabidiol (CBD) and all other nonpsychoactive cannabinoids. Patents are also granted…

Continue Reading